The Competition and Markets Authority (CMA) has provisionally found that, from July 2011 to April 2015, the sole supplier of hydrocortisone tablets in the UK, Auden Mckenzie, and its rival, Waymade, entered into anti-competitive agreements.
This may also have involved Auden Mckenzie abusing its dominant position by making monthly payments to Waymade not to enter the market. The CMA has today issued its concerns in a ‘Statement of Objections’ to the companies involved.
As a result of this alleged anti-competitive behavior, the CMA believes the NHS was denied a choice of suppliers and the potential savings resulting from increased competition.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
EU Tech Firms Advocate for Sovereign Infrastructure Fund to Boost Tech Independence
Mar 17, 2025 by
CPI
Trump Administration Seeks to Extend Deadlines in U.S. Steel and Nippon Steel Lawsuit
Mar 17, 2025 by
CPI
DOJ Antitrust Chief to Review Costly Consultants Amid Spending Cuts
Mar 17, 2025 by
CPI
DOJ Antitrust Chief Gail Slater Assembles Veteran Team for Key Cases
Mar 16, 2025 by
CPI
UK Demands Access to Apple’s Encrypted Cloud Data, Spark Legal and Privacy Battle
Mar 16, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Self-Preferencing
Feb 26, 2025 by
CPI
Platform Self-Preferencing: Focusing the Policy Debate
Feb 26, 2025 by
Michael Katz
Weaponized Opacity: Self-Preferencing in Digital Audience Measurement
Feb 26, 2025 by
Thomas Hoppner & Philipp Westerhoff
Self-Preferencing: An Economic Literature-Based Assessment Advocating a Case-By-Case Approach and Compliance Requirements
Feb 26, 2025 by
Patrice Bougette & Frederic Marty
Self-Preferencing in Adjacent Markets
Feb 26, 2025 by
Muxin Li